6th IAS Conference On HIV Pathogenesis, Treatment and Prevention


Efficacy and safety of lersivirine (UK-453,061) vs. efavirenz in antiretroviral treatment-naïve HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicentre, randomised, double-blind, phase IIb trial (study A5271015) TUAB0101


Time: 11:00
Speaker: Anton Pozniak




You can download the mp3 file here



For more information on this presentation, including access to speaker presentations, please see the conference Programme-at-a-Glance page.


Contact Us | Site map © 2011 International AIDS Society